Joshua Schimmer


UPDATE: Piper Jaffray Maintains Buy On GW Pharmaceuticals Following Sativex Phase III Results

In a research report published today, Piper Jaffray analyst Joshua Schimmer maintained an Overweight rating on GW Pharmaceuticals (NASDAQ:GWPH) with a price target of $147, …

Piper Jaffray Comments On Gilead Sciences As Express Scripts Picks AbbVie For Hepatitis C Drug

In a research report issued today, Piper Jaffray analyst Joshua Schimmer weighed in with his thoughts on Gilead Sciences (NASDAQ:GILD), following the news that Express Scripts (NASDAQ:ESRX) has …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts